Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis

Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon α-2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jing-Hong, Chang, Ming-Ling, Liu, Nai-Jen, Yeh, Chau-Ting, Huang, Tung-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777273/
https://www.ncbi.nlm.nih.gov/pubmed/31602234
http://dx.doi.org/10.3892/etm.2019.7995
_version_ 1783456595780304896
author Hu, Jing-Hong
Chang, Ming-Ling
Liu, Nai-Jen
Yeh, Chau-Ting
Huang, Tung-Jung
author_facet Hu, Jing-Hong
Chang, Ming-Ling
Liu, Nai-Jen
Yeh, Chau-Ting
Huang, Tung-Jung
author_sort Hu, Jing-Hong
collection PubMed
description Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon α-2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels. The present meta-analysis aimed to evaluate the effect of HCV treatment response on IR in HCV patients who achieved SVR and those who did not (non-SVR) after receiving interferon (IFN)-based therapy. The PubMed, Cochrane and Embase databases were searched using combinations of the following search terms: ‘HCV’, ‘hepatitis C’, ‘interferon’, ‘antiviral’, ‘treatment response’ and ‘insulin resistance’. The incidence of IR, HOMA-IR and HOMA-β, as well as fasting glucose and fasting insulin levels, were summarized in terms of basal values and values after the end of treatment for each study. A total of 8 studies were included in the final analysis. There was no significant difference in the reduction in IR between the SVR and non-SVR groups (odds ratio, 0.995; 95% CI=0.613–1.616; P=0.984). However, the SVR group had a significantly higher mean reduction in HOMA-IR (difference in means=−0.485; 95%CI=−0.713 to −0.256; P<0.001) and HOMA-β (difference in means=−15.448; 95%CI=−23.326 to −7.570; P<0.001) compared to the non-SVR group. In conclusion, HCV patients who achieved SVR after IFN-based therapy exhibited improvement in HOMA-IR and HOMA-β. The present results suggest that clinical management of IR and serum glucose levels may be an important way to impact the therapeutic response in HCV patients.
format Online
Article
Text
id pubmed-6777273
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-67772732019-10-10 Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis Hu, Jing-Hong Chang, Ming-Ling Liu, Nai-Jen Yeh, Chau-Ting Huang, Tung-Jung Exp Ther Med Articles Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon α-2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels. The present meta-analysis aimed to evaluate the effect of HCV treatment response on IR in HCV patients who achieved SVR and those who did not (non-SVR) after receiving interferon (IFN)-based therapy. The PubMed, Cochrane and Embase databases were searched using combinations of the following search terms: ‘HCV’, ‘hepatitis C’, ‘interferon’, ‘antiviral’, ‘treatment response’ and ‘insulin resistance’. The incidence of IR, HOMA-IR and HOMA-β, as well as fasting glucose and fasting insulin levels, were summarized in terms of basal values and values after the end of treatment for each study. A total of 8 studies were included in the final analysis. There was no significant difference in the reduction in IR between the SVR and non-SVR groups (odds ratio, 0.995; 95% CI=0.613–1.616; P=0.984). However, the SVR group had a significantly higher mean reduction in HOMA-IR (difference in means=−0.485; 95%CI=−0.713 to −0.256; P<0.001) and HOMA-β (difference in means=−15.448; 95%CI=−23.326 to −7.570; P<0.001) compared to the non-SVR group. In conclusion, HCV patients who achieved SVR after IFN-based therapy exhibited improvement in HOMA-IR and HOMA-β. The present results suggest that clinical management of IR and serum glucose levels may be an important way to impact the therapeutic response in HCV patients. D.A. Spandidos 2019-11 2019-09-11 /pmc/articles/PMC6777273/ /pubmed/31602234 http://dx.doi.org/10.3892/etm.2019.7995 Text en Copyright: © Hu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Hu, Jing-Hong
Chang, Ming-Ling
Liu, Nai-Jen
Yeh, Chau-Ting
Huang, Tung-Jung
Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis
title Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis
title_full Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis
title_fullStr Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis
title_full_unstemmed Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis
title_short Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis
title_sort effect of hcv treatment response on insulin resistance: a systematic review and meta-analysis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777273/
https://www.ncbi.nlm.nih.gov/pubmed/31602234
http://dx.doi.org/10.3892/etm.2019.7995
work_keys_str_mv AT hujinghong effectofhcvtreatmentresponseoninsulinresistanceasystematicreviewandmetaanalysis
AT changmingling effectofhcvtreatmentresponseoninsulinresistanceasystematicreviewandmetaanalysis
AT liunaijen effectofhcvtreatmentresponseoninsulinresistanceasystematicreviewandmetaanalysis
AT yehchauting effectofhcvtreatmentresponseoninsulinresistanceasystematicreviewandmetaanalysis
AT huangtungjung effectofhcvtreatmentresponseoninsulinresistanceasystematicreviewandmetaanalysis